Rationale for a phase III clinical trial with AE-941 (Neovastat (R)) in metastatic renal cell carcinoma patients refractory to immunotherapy.

ANNALS OF ONCOLOGY(2000)

引用 0|浏览2
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要